PIN33 UTILIZATION PATTERNS OF MEDICAL SERVICES AND PRESCRIPTION DRUGS FOR THE TREATMENT OF TINEA CAPITIS  by Suh, DC et al.
360 Abstracts
number of AB’s used. The mean (median) cost for parenteral AB-
therapy was 624.2 (275.3) Euro versus 504.4 (169.1) Euro for
SDT (p < 0.001 Anova). CONCLUSIONS: MBDS through ICD-
9-CM yields valuable information on “real life practice”. The
antibiotic-related cost in SDT is signiﬁcantly lower than full par-
enteral treatment; LOS corrected for age, gender, reason for
admission and departure was unaffected.
INFECTIONS
INFECTIONS—Quality of Life Studies
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SUBSTITUTION TO LOPINAVIR/RITONAVIR (LPV/R) IS
ASSOCIATED WITH IMPROVED PATIENT-REPORTED FATIGUE
IN HIV+ PATIENTS EXPERIENCING SIDE EFFECTS RELATED
TO THEIR PROTEASE INHIBITOR (PI)/NON-NUCLEOSIDE
REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)
Luo MP, Shen Y, Rode R, McMillan F,Tressler R,Ashraf T
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: Fatigue is a common, distressing symptom in
HIV+ patients. This analysis evaluates whether substitution to
LPV/r, a generally well tolerated and efﬁcacious PI, affects fatigue
in HIV+ patients experiencing Grade 2 side effects (SE) attrib-
uted to their PI/NNRTI. METHODS: In the open-label PLATO
trial, patients experiencing Grade 2 PI/NNRTI-associated SE
were randomized (4:1) to immediate substitution (IS) of their
PI/NNRTI with LPV/r at baseline or deferred substitution (DS)
at Week 4 (Wk4). The MOS-HIV and ACTG Symptoms Distress
Module, with 2 additional items for nephrolithiasis (ASDM),
were administered at baseline, Wk4 and Wk8. Fatigue was 
measured by MOS-HIV fatigue-domain and ASDM fatigue/
bothersomeness-item. Sleep-disorder was measured by ASDM
sleep-disorder-item. The Center for Epidemiologic Studies-
Depression (CES-D) questionnaire was administered at baseline
and Wk8. RESULTS: Eight hundred twenty-seven patients 
previously on nelﬁnavir (n = 291), indinavir (n = 170), indi-
navir/ritonavir (n = 182), efavirenz (n = 136) or another
PI/NNRTI (n = 48) were analyzed (80% male, mean age 42yrs,
75% with baseline HIV RNA <50 copies/mL). At baseline, mean
MOS-HIV fatigue-domain score was 56.7, with 62.3% rating
fatigue as bothersome. Baseline fatigue scores were correlated 
(p < 0.05) with presence of depression (CES-D >= 16), sleep-
disorder, and years since HIV diagnosis. At Wk4, improved
fatigue scores were seen in IS vs. DS groups (MOS-HIV fatigue-
domain: +8.711 vs. +0.068, p < 0.001; ASDM fatigue/
bothersomeness-item: -0.486 vs. +0.074, p < 0.001), irrespective
of prior PI/NNRTI regimens. At Wk8, fatigue improvement
remained for IS group, while DS group began to improve.
Improved fatigue scores were associated (p < 0.05) with IS,
reduced prevalence of depression, and improved sleep-disorder
scores. Improvement in fatigue and IS were signiﬁcant predictors
of improved MOS-HIV physical health summary score at Wk4
(p < 0.05). CONCLUSIONS: Fatigue scores were improved fol-
lowing substitution with LPV/r, and were associated with
reduced prevalence of depression and improved sleep-disorder
scores. Improvement in fatigue was independent of prior




ACUTE SINUSITIS IN MANAGED CARE: ANTIBIOTIC
TREATMENT AND OUTCOMES
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OBJECTIVE: To examine antibiotic prescribing and outcomes
associated with acute sinusitis in managed care. METHODS:
We used the PharMetrics claims database for 8 managed care
organizations. Index claims were based on outpatient visits in
1999–2001 by individuals aged 45–64 with a primary diagnosis
of acute sinusitis who received an antibiotic within 7 days and
were continuously enrolled for 12 months prior to and 45 days
after the index event. Exclusion criteria: antibiotic prescription
or sinusitis diagnosis in prior 45 days, hospitalization in 
prior 30 days, or sinus complications in prior 12 months. Broad
spectrum antibiotics (BSA) were deﬁned as: azithromycin, 
clarithromycin, amoxicillin-clavulanate, second- and third-
generation cephalosporins, quinolones. Sinusitis history was 
categorized: chronic sinusitis (HxChr), acute but not chronic
sinusitis (HxAcu), no history (NoHx). Also, subjects with
asthma, chronic obstructive pulmonary disease (COPD), lower
and upper respiratory tract infection (LRTI, URTI),and rhinitis
in prior year were identiﬁed. Multivariate models adjusted for
age, sex, health plan, use of laboratory/diagnostic testing at
initial evaluation (surrogate for severity and practice variation).
RESULTS: Out of 64,277 cases, 66.1% female, met criteria. Res-
piratory history: 5.4% HxChr, 7.9% HxAcu, 4.5% asthma,
4.4% COPD, 24.6% URTI, 16.3% LRTI, 10.4% rhinitis. BSA
accounted for 45.5% of 1st-line prescriptions. BSA use increased
over 3 years (p < 0.0001): 43.8% (1999), 45.5% (2000), 49.2%
(2001). BSA use was highest for HxChr and asthma at 54.3%.
Overall, 22.4% received a 2nd prescription, highest among
HxChr, 31.7%. Mean charges were $134; highest for HxChr,
$158 and asthma, $152. In multivariate models, respiratory his-
tories were positively associated (p < 0.05) with BSA use, 2nd
prescriptions and charges. CONCLUSION: In treatment of acute
sinusitis in managed care, broad spectrum antibiotics are used
almost 50% of the time as initial therapy and use is rising. Res-
piratory history, especially chronic sinusitis or asthma, is associ-
ated with more BSA use, 2nd prescriptions, and charges.
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UTILIZATION PATTERNS OF MEDICAL SERVICES AND
PRESCRIPTION DRUGS FOR THE TREATMENT OF TINEA
CAPITIS
Suh DC1, Raut M2, Chang J2,Valiyeva E1,Tavakkol A2,Vo L1
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OBJECTIVES: This study was conducted to examine the uti-
lization patterns of medical services and prescription drugs in
patients with tinea capitis (TC). METHODS: This retrospective
cohort study identiﬁed TC patients using the MarketScan® data-
base during January 1, 1999–December 31, 2002. Patients were
selected if they had primary or secondary diagnosis of TC (ICD-
9 Code of 110) and had continuous health insurance and pre-
scription drug coverage. The identiﬁed patients were deﬁned as
newly diagnosed patients if they were not diagnosed with TC or
did not use any prescription drugs for TC treatment in the pre-
vious year. The frequency of medical services and the usage pat-
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terns of prescription drugs were analyzed using SAS statistical
software. RESULTS: A total of 3120 and 2791 patients with TC
were identiﬁed in 2000 and 2001 respectively. The overall trends
in 2000 were similar to those of 2001. In 2001, TC patients
visited their physician ofﬁce 1.3 times per year: 79% visited once
a year, 15%-twice, 6%-more than twice. Three percentages of
the patients continued to visit their physician ofﬁce in the second
year. Seventy-nine percent of the patients used at least 1 pre-
scription for TC treatment, and 73% used an antifungal oral
and/or topical agent. TC patients used an oral antifungal for 25
days on average. About 25% of the patients used an oral anti-
fungal as monotherapy, the most common therapy. Among oral
antifungals, griseofulvin was the most frequently used medica-
tion (41%), followed by terbinaﬁne (9%). Among newly diag-
nosed patients, 73% used prescription drugs in the ﬁrst year and
23% in the following year. CONCLUSIONS: TC patients used
medical services and prescription drugs substantially in the year
of diagnosis and many of these patients continuously used pre-
scription drugs due to relapse of the symptoms in the following
year. More effective therapy for TC could reduce the need for
subsequent therapy.
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THE USE OF ANTIBIOTICS TO TREAT ACUTE UPPER
RESPIRATORY TRACT INFECTIONS IN A STATE 
MEDICAID POPULATION
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There is a growing concern in the United States regarding antibi-
otic resistance due to inappropriate prescribing of antibiotics.
OBJECTIVES: Report the patterns of oral antibiotics ﬁlled fol-
lowing a medical visit for upper respiratory infection (URI) in a
state Medicaid population. METHODS: The study sample
included Medicaid recipients who had an outpatient or emer-
gency department (ED) visit in 2002 for an acute URI. Outpa-
tient and ED claims with a primary ICD-9-CM diagnosis code
for acute nasopharyngitis, acute pharyngitis, acute URI, acute
bronchitis, or inﬂuenza were extracted. Prescription claims for
antibiotics ﬁlled within ﬁve days following a URI-related medical
visit also were extracted. RESULTS: A total of 21,163 recipients
were included in the study. Over 71% of the recipients were
female, and nearly 95% were white. Recipients between 21 to
44 years of age accounted for more than half of the study group.
Nearly half of all recipients made only one visit for URI through-
out the year, and over 28% made 3 or more visits. Oral antibi-
otics accounted for roughly 10% of the total prescriptions ﬁlled
within 5 days following an acute URI-related medical visit. These
antibiotics were for penicillins (41%), cephalosporins (15%),
macrolides (11%), and others including quinolones, tetracy-
clines, sulfonamides and trimethoprim (33%). CONCLUSION:
One out of every ten prescriptions ﬁlled following an acute 
URI-related medical visit among recipients of Medicaid was for
an oral antibiotic. Many upper respiratory tract infections 
are viral in nature, in which oral antibiotic treatment may be
inappropriate.
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MEN’S HEALTH—Clinical Outcomes Studies
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OBJECTIVE: To assess the validity and reliability of the self-
administered Spanish version of the LISAT 8 as a screening tool
for male ED in primary care settings. METHODS: A total of 653
subjects (537 ED and 116 nonED), >18 years, who reported
attempting sexual activity and managed at Primary Care level,
were extracted from a study designed to perform the cultural
adaptation and validation into Spanish of the LISAT 8. Multi-
variate logistic regression was applied to detect items or scale
domains capable to be predictors of ED, and the ROC curves
analysis to determine optimal cutoff score showing the best clini-
metric indicators for sensitivity, speciﬁcity and positive and neg-
ative predictive values to distinguish between ED and non ED
subjects. Positive and negative likelihood ratios, area under the
curve of the optimal cutoff score and kappa coefﬁcient of agree-
ment were also calculated. RESULTS: Items 2 and 8 of the check
list (satisfaction with sexual life and satisfaction with partner
relationship) which forms the affective domain of the instrument,
were found to be predictors for ED. Mean (+standard deviation)
for affective domain was signiﬁcantly higher in nonED than in
ED subjects; 9.2 + 2.1pts versus 5.6 + 1.8pts, p < 0.0001. This
domain showed moderate, but statistically signiﬁcant, correla-
tion coefﬁcients with IIEF and with each of its 5 domains (coef-
ﬁcients ranged between 0.44 and 0.69). ROC curves analysis
showed an optimal cutoff score for ED of <8pts; area under the
curve = 0.892, p < 0.0001; sensitivity, 0.87; speciﬁcity, 0.84; pos-
itive predictive value, 0.96; negative predictive value, 0.58; and
kappa agreement coefﬁcient = 0.602, p < 0.0001. CONCLU-
SION: The domain satisfaction with affective life (items 2 and
3) of the Spanish version of the LISAT 8 showed adequate clini-
metric properties of validity and reliability as a screening tool
for male erectile dysfunction in Primary Care level.
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ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION (ADSD)
IN EUROPE:A PRELIMINARY INVESTIGATION
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OBJECTIVE: Sexual dysfunction is a common side effect of
selective serotonin reuptake inhibitor (SSRI) antidepressants.
Although widely acknowledged by US patients and physicians,
this side effect is not as readily recognized in Europe. The goal
of this study was to obtain preliminary estimates regarding the
prevalence and impact of ADSD in two European countries.
METHODS: This cross-sectional survey involved a total of 502
adults in France and the UK. All participants were taking an SSRI
that had been newly prescribed within the previous three
months. Information was gathered about patients’ current
depression treatment, other medications and conditions known
to impair sexual functioning, recent changes in sexual function-
ing, and the impact of any such changes. The Medical Outcomes
